- Stockholders’ equity significantly surpasses the $2.5 million minimum required by Nasdaq - Company is to seek Nasdaq’s formal confirmation...
HANOVER, Md., May 06, 2024 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), a clinical-stage pharmaceutical...
Final results demonstrate a significantly higher salvage treatment free survival rate (STFS) at 30 months of 89.6% in the...
Encouraging response rate shown; CR in 67% (6/9) of patients who completed the Induction Treatment Phase Padeliporfin VTP generally well-tolerated,...
ANGLE commissioned to develop a Parsortix-based Androgen Receptor detection assay for use in prostate cancer studies GUILDFORD, SURREY / ACCESSWIRE...
NEW YORK--(BUSINESS WIRE)--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women’s health and wellness,...
TORONTO, ON / ACCESSWIRE / May 2, 2024 / Theralase® Technologies Inc. ("Theralase®" or the "Company") (TSXV:TLT)(OTCQB:TLTFF), a clinical stage...
Reports first quarter revenues of $167 million, GAAP net loss of $1.2 billion and GAAP diluted EPS of $(3.07)Prepares for...
BURLINGAME, Calif., May 02, 2024 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Corvus or the Company) (Nasdaq: CRVS) (GLOBAL NEWSWIRE), a...
MIAMI, FL, May 02, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on...
CAMBRIDGE, Mass., May 02, 2024 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering...
Adam Hughes, Ph.D. Chief Scientific Officer, Vicinitas Therapeutics SOUTH SAN FRANCISCO, Calif., May 02, 2024 (GLOBE NEWSWIRE) -- Vicinitas Therapeutics,...
Boston (May 2, 2024)—Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a clinical-stage pharmaceutical company dedicated to developing personalized...
Company to host conference call and webcast on Thursday, May 16th at 8:30am EDT LYON, France, May 2, 2024 --...
Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)PRINCETON, N.J., May 02, 2024 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB)...
NASHUA, N.H., May 02, 2024 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a global leader in clinically proven AI-powered cancer...
Aiming to Combat Skin Cancer with Community Shade InitiativesOTTAWA, May 02, 2024 (GLOBE NEWSWIRE) -- The Canadian Dermatology Association (CDA)...
BASKING RIDGE, N.J., May 02, 2024 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage...
Media Release Novel triple combination of efti with radiotherapy and anti-PD-1 therapy is well tolerated and has led to encouraging...
Reported positive data from three-month evaluable CIS patients treated across ongoing TARA-002 clinical program in NMIBCPreliminary data from six-month evaluable...